AntoXa

Life-saving biodefense solutions

  • About Us
    • Management Team
  • Products
  • Investors
  • News
  • Contact
You are here: Home / News

News

Welcome to AntoXa Corporation’s newsroom.

For media inquiries, please contact:

Stacey Curry Gunn
Director of Communications
stacey.curry.gunn@antoxacorp.com
519.827.1131

See below for links to the latest AntoXa news.


 

AntoXa Corporation awarded contract extension with federal government to develop plant-made protein for potential coronavirus therapy

DRDC-funded project aims to develop recombinant human angiotensin-converting enzyme 2 (ACE2) as a potential drug candidate for COVID-19 GUELPH, Ontario, Canada, August 17, 2021 — Canadian biopharmaceutical company AntoXa Corporation has been awarded a contract extension from the Government of Canada that includes development of plant-made recombinant human angiotensin-converting enzyme ...
Continue reading ...
August 17, 2021 / ACE2, BuCHE, COVID-19, DRDC, News Releases

AntoXa awarded federal government contract for anti-nerve agent enzyme

GUELPH, Ontario, Canada, March 20, 2019 — AntoXa Corporation has been awarded a contract with the Government of Canada to continue work on production of plant-made butyrylcholinesterase (BuChE), a protein that provides protection against toxic nerve agents such as sarin and soman. The one-year contract, worth up to $329,395, with ...
Continue reading ...
March 20, 2019 / Anti-Nerve Agents, News Releases

Ashley J. Meyers appointed President and COO of AntoXa Corporation

Guelph, Ont., Canada, Dec. 20, 2018 — AntoXa Corporation announced today that Ms. Ashley J. Meyers has been appointed President and Chief Operating Officer (COO). Ashley J. Meyers, President and COO of AntoXa Corporation. Ms. Meyers has been a member of the Canadian biopharmaceutical company’s leadership team since the company’s ...
Continue reading ...
December 20, 2018 / Management Team, News Releases

Ron Hosking appointed to AntoXa Corporation Board of Directors

Guelph, Ont., Canada, Nov. 28, 2018 — Ron Hosking, CPA, CA, has been appointed to the AntoXa Corporation Board of Directors, effective immediately. Mr. Hosking is a chartered accountant with three decades of experience as a financial manager in the biotechnology and pharmaceutical industries. He is also Chief Financial Officer ...
Continue reading ...
November 28, 2018 / Management Team, News Releases

AntoXa Corporation granted Defence R&D Canada license for novel, plant-made anti-ricin antibody

GUELPH, Ont., Canada, April 16, 2018— AntoXa Corporation has obtained a license from Defence Research & Development Canada (DRDC), an Agency of the Canadian Department of National Defence, to develop and produce an anti-ricin monoclonal antibody for sale in markets worldwide. The licensing agreement follows work AntoXa and the J.C ...
Continue reading ...
April 16, 2018 / News Releases, Products
  • 1
  • 2
  • ›
Loading...

Latest News

AntoXa Corporation awarded contract extension with federal government to develop plant-made protein for potential coronavirus therapy

August 17, 2021

DRDC-funded project aims to develop recombinant human ...
Read more >

AntoXa awarded federal government contract for anti-nerve agent enzyme

March 20, 2019

GUELPH, Ontario, Canada, March 20, 2019 — AntoXa Corporation has been ...
Read more >

Ashley J. Meyers appointed President and COO of AntoXa Corporation

December 20, 2018

Guelph, Ont., Canada, Dec. 20, 2018 — AntoXa Corporation announced today ...
Read more >

About Us

Plant-made biopharmaceuticals for a safer world. AntoXa Corporation is a Canadian biopharmaceutical company developing medical countermeasures to protect military and civilian personnel from biological and chemical agents that might be used in terrorist attacks, as well as outbreaks of naturally ...
Read more >

Global Demand for Biodefense Therapeutics

Governments are investing billions of dollars preparing for potential bioterrorism attacks and ...
Read more >

Subscribe to our Newsletter

vivoXPRESS® MANUFACTURING SYSTEM
The tobacco-plant-based vivoXPRESS® manufacturing platform offers several advantages over the mammalian and bacterial cell culture systems used to produce most recombinant protein pharmaceuticals. Here’s how it works.

BioPharming Info Centre

Biopharming, also known as plant molecular farming, refers to the use of genetically modified plants to produce a wide range of pharmaceuticals and industrial products. See our Biopharming Info Centre to Learn more about the science and history of using plants to produce complex therapeutic proteins.

Copyright © 2023 · AntoXa Corporation | Site by Curry Gunn & Associates